Media Articles Related to Recombivax HB (Hepatitis B Vaccine)
Influenza Vaccination Rates Up; Goal Not Met in Asthmatics
Source: Medscape Medical News Headlines [2013.12.06]
From 2010 to 2011, 50% of people with asthma received the influenza vaccine, which is an increase from 36% just 5 years earlier but still below the goal of 80% in children and 90% in adults.
Medscape Medical News
Chickenpox vaccination not linked to increased shingles incidence
Source: Immune System / Vaccines News From Medical News Today [2013.12.03]
A new study claims to have ruled out a link between childhood vaccination against varicella (chickenpox) and the increased incidence of herpes zoster (shingles) in adults, according to an article published in the Annals of Internal Medicine.Chickenpox and shingles are both caused by the same virus - the varicella zoster virus (VZV).
FDA study helps provide an understanding of rising rates of whooping cough and response to vaccination
Source: Immune System / Vaccines News From Medical News Today [2013.11.29]
A new study is helping to provide a better understanding of vaccines for whooping cough, the common name for the disease pertussis. Based on an animal model, the study conducted by the U.S.
Vaccinations: One more weapon in the fight against antibiotic resistance
Source: Immune System / Vaccines News From Medical News Today [2013.11.26]
Doctors, pharmacists and nurses are being asked to encourage their patients to keep up with the vaccinations recommended in the National Immunisation Program (NIP) schedule, as immunisation can help reduce the rates of vaccine-preventable diseases that may have required antibiotics to treat them or their complications.
Study examines barriers to human papillomavirus vaccination among teens
Source: Sexual Health / STDs News From Medical News Today [2013.11.26]
Barriers to human papillomavirus (HPV) vaccination among adolescents in the U.S. range from financial concerns and parental attitudes to social influences and concerns about the vaccination's effect on sexual behavior, according to a review of the available medical literature published by JAMA Pediatrics, a JAMA Network publication.
Published Studies Related to Recombivax HB (Hepatitis B Vaccine)
Safety and immunogenicity of a modified process hepatitis B vaccine in healthy infants. [2011.07]
BACKGROUND: A modified process hepatitis B vaccine (mpHBV) uses higher phosphate content in the manufacturing process relative to the current product, Recombivax-HB. The higher phosphate is thought to improve antigen presentation, and thereby, increase antibody production. The mpHBV was previously shown to be well tolerated and immunogenic in adults. The current study tested a 2-, 4-, 6-month vaccination schedule and a higher dose formulation (10 mug mpHBV) in healthy infants... CONCLUSIONS: All 4 hepatitis B vaccines elicited high anti-HBs SPRs. After dose 3, anti-HBs GMT were highest in the 10 mug mpHBV group, but did not meet the predefined criteria for superiority. All vaccines were well tolerated.
Immunogenicity and safety of an investigational hexavalent diphtheria-tetanus-acellular pertussis-inactivated poliovirus-hepatitis B-Haemophilus influenzae B conjugate combined vaccine in healthy 2-, 4-, and 6-month-old Argentinean infants. [2011.06]
BACKGROUND AND AIMS: Assessment of a new, fully liquid, investigational hexavalent DTaP-IPV-Hep B-PRP-T vaccine (Hexaxim, Sanofi Pasteur), containing the same active ingredients as Pentaxim (DTaP-IPV//PRT-T) and 10 mug Hansenula polymorpha-derived recombinant hepatitis B (Hep B) surface antigen, Sanofi Pasteur, in Argentinean infants... CONCLUSIONS: The new, fully liquid, investigational DTaP-IPV-Hep B-PRP-T vaccine (Hexaxim) is highly immunogenic and safe when compared with licensed comparators, warranting further development.
Effect of high-flux hemodialysis on delayed hepatitis B virus vaccination response in hemodialysis patients. [2011.05]
OBJECTIVES: The aim of the study was to evaluate the effect of high-flux (HF) hemodialysis (HD) on delayed protective hepatitis B virus (HBV) antibody seroconversion in HD patients who had no response to the classic third dose of HBV vaccination... CONCLUSION: Hemodialysis patients who do not respond to the classic third dose of HBV vaccination could reobtain a delayed higher protective HBV antibody seroconversion rate by HF HD without other intervention.
Vaccination against hepatitis B among prisoners in Iran: accelerated vs. classic vaccination. [2011.05]
BACKGROUND: Prisoners and injecting drug users are at constant risk of hepatitis B virus (HBV) infection and the classic 6-months HBV vaccination might not provide immunization rapidly enough. In this randomized clinical trial we investigated the efficacy of an accelerated vaccination protocol vs. classic schedule among prisoners in Iran... CONCLUSION: Compared to classic HBV vaccination regimen, an accelerated 0, 1, 4 and 8 weeks vaccination schedule can achieve early seroprotection more rapidly, provides clinically sufficient seroprotection with higher compliance in prisoners and can be suggested in situations that rapid immunization against HBV infection is warranted. Copyright (c) 2011 Elsevier Ireland Ltd. All rights reserved.
Safety and immunogenicity of 4 intramuscular double doses and 4 intradermal low doses vs standard hepatitis B vaccine regimen in adults with HIV-1: a randomized controlled trial. [2011.04.13]
CONTEXT: Alternative schedules more immunogenic than the standard hepatitis B vaccine regimen are needed in patients with human immunodeficiency virus 1 (HIV-1) infection. OBJECTIVE: To compare the safety and immunogenicity of 4 intramuscular double-dose and 4 intradermal low-dose regimens vs the standard hepatitis B vaccine regimen... CONCLUSION: In adults with HIV-1, both the 4 intramuscular double-dose regimen and the 4 intradermal low-dose regimen improved serological response compared with the standard HBV vaccine regimen. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT00480792.
Clinical Trials Related to Recombivax HB (Hepatitis B Vaccine)
Effectiveness of Two Hepatitis B Vaccines in HIV-Negative Youths [Active, not recruiting]
This study will evaluate 2 licensed vaccine products (Recombivax and Twinrix) given in a
two-dose schedule to youth at risk for hepatitis B and HIV infection to evaluate
immunogenicity of the products in this population, barriers to vaccine delivery, and factors
which predict a diminished immune response. Since these youths are also potential candidates
for future HIV vaccine trials, this study will also include preliminary assessment of youths'
understanding of informed consent forms, and willingness to participate in a vaccine trial
and return for multiple visits (including blood draws for immunologic assessment).
Immunologic Memory (Supp. of ATN 024) [Completed]
This is an exploratory, laboratory-based evaluation of cellular immune response to
immunization with hepatitis B surface antigen in HIV-infected and HIV-uninfected adolescents.
This is a substudy of ATN 024 and ATN 025. This substudy will compare cellular immune
response in responders and nonresponders to immunization and also evaluate the relationship
of these factors to the persistence of known correlates of serologic protection for the
hepatitis B virus.
Modified Process Hepatitis B Vaccine in Japanese Young Adults (V232-062) [Not yet recruiting]
This is a study to evaluate immunogenicity, safety, and tolerability of 2XP HEPTAVAX-II
compared with the 1XP HEPTAVAX-II in healthy Japanese young adults.